Cancer cell · 2009
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Sidong, Laoukili Jamila, Epping Mirjam T, Koster Jan, Hölzel Michael, Westerman Bart A, Nijkamp Wouter, Hata Akiko, Asgharzadeh Shahab, Seeger Robert C, Versteeg Rogier, Beijersbergen Roderick L, Bernards René
Аннотация
Retinoids play key roles in differentiation, growth arrest, and apoptosis and are increasingly being used in the clinic for the treatment of a variety of cancers, including neuroblastoma. Here, using a large-scale RNA interference-based genetic screen, we identify ZNF423 (also known as Ebfaz, OAZ, or Zfp423) as a component critically required for retinoic acid (RA)-induced differentiation. ZNF423 associates with the RARalpha/RXRalpha nuclear receptor complex and is essential for transactivation in response to retinoids. Downregulation of ZNF423 expression by RNA interference in neuroblastoma cells results in a growth advantage and resistance to RA-induced differentiation, whereas overexpression of ZNF423 leads to growth inhibition and enhanced differentiation. Finally, we show that low ZNF423 expression is associated with poor disease outcome in neuroblastoma patients.
Предметные рубрики MeSH
AdolescentAntineoplastic AgentsCell DifferentiationChildChild, PreschoolChromatin ImmunoprecipitationDNA-Binding ProteinsFemaleHumansInfantInfant, NewbornMaleNeuroblastomaPrognosisPromoter Regions, GeneticProteinsReceptors, Retinoic AcidRetinoic Acid Receptor alphaSurvival RateTeratocarcinomaTretinoinZinc Fingers